
Neu
Smartphone platform for Parkinson's and dementia care.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor | €0.0 | round |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
* | N/A | Grant | |
Total Funding | 000k |
USD | 2023 |
---|---|
Revenues | 0000 |
EBITDA | 0000 |
Profit | 0000 |
EV | 0000 |
EV / revenue | 00.0x |
EV / EBITDA | 00.0x |
R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Neu Health is a health-tech company that spun out of the University of Oxford in 2022. Founded by Caroline Cake and Dr. Kinan Muhammed, the London-based firm aims to make modern care for Parkinson's disease and dementia more accessible. The company is built on over a decade of research and clinical validation from the University of Oxford.
Neu Health has developed a digital platform that uses a patient's smartphone to monitor and analyze symptoms related to neurological conditions. The system combines a patient-facing app with a dashboard for clinicians. Through the app, which requires about seven minutes of use, patients perform tasks that allow the platform's AI and machine learning algorithms to measure motor and cognitive functions, such as tremor, balance, speech, and memory. This data provides healthcare providers with objective, trackable metrics and predictive insights into disease progression, with the capability to forecast significant clinical outcomes up to 18 months in advance. The platform is designed to improve clinical outcomes by enabling more personalized and data-driven care, while also offering educational resources and support for medication adherence.
The company operates on a B2B2P (business-to-business-to-patient) model, partnering with healthcare providers who then prescribe the app to their patients. In early 2025, Neu Health secured €1.9 million in funding from Oxford Science Enterprises and Cedars-Sinai Intellectual Property Company to support its expansion into the U.S. market. This expansion includes a pilot program at Cedars-Sinai with 150 patients. The platform is also in use at Mass General Brigham in Boston and several hospitals in the UK. In August 2025, Neu Health received FDA 510(k) clearance for its smartphone-based tremor measurement module.
Keywords: digital neurology care, Parkinson's disease, dementia, health-tech, remote patient monitoring, clinical decision support, AI in healthcare, neurodegenerative diseases, smartphone diagnostics, machine learning, data analytics, Oxford University spinout, motor symptom tracking, cognitive function assessment, personalized medicine